DRAM1 and neoplasm: DRAM1-mediated reduction of mutant EGFR enhanced the cytotoxicity of TKI, and the overexpression of DRAM1 inhibited the growth, migration and invasion of NSCLC in vitro and in vivo, indicating that decrease in DRAM1 expression was beneficial to EGFR mutant NSCLC cells, supporting that DRAM1 has a tumor suppressor activity.